Publications by authors named "Juan M Reyes"

Introduction: Hemophilia A and B are disorders associated with the deficit of coagulation factors VIII and IX.

Objective: Was to determine the incidence of complications in a cohort of patients diagnosed with moderate and severe hemophilia A or B under treatment in a specialized institution.

Methods: A retrospective study of a cohort of patients with replacement therapy for hemophilia A or B, evaluating treatment and complications between January/2012 and July/2019.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on Colombian patients with non-valvular atrial fibrillation (NVAF) using oral anticoagulants, analyzing their characteristics and treatment outcomes.
  • A total of 2076 patients were examined, revealing that the majority were older women with common conditions like hypertension and diabetes, with rivaroxaban being the most prescribed OA.
  • While thrombotic event rates were similar between warfarin and direct oral anticoagulants, warfarin users experienced significantly more bleeding complications and had lower treatment persistence.
View Article and Find Full Text PDF

Background And Aims: A noninterventional prospective study was performed in Colombia and Peru. The aim was to describe the impact of access to treatment on Patient-reported outcomes (PRO) in patients with Rheumatoid arthritis (RA) after failure to conventional disease-modifying antirheumatic drugs (DMARDs) in real-life conditions.

Methods: The impact of access to treatment was measured by access barriers, time to supply (TtS) and interruption evaluating their effect in changes of PROs between baseline and 6-month follow-up between February 2017 and November 2019.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates the cost-effectiveness of tofacitinib versus other treatments for moderate to severe ulcerative colitis in Colombia, focusing on first-line and second-line patients.
  • A Markov model was used to simulate patient outcomes over 5 years, assessing transitions between health states and measuring effectiveness using quality-adjusted life-years (QALYs).
  • The results indicate that tofacitinib is more cost-effective than infliximab and adalimumab in both treatment lines, particularly showing a cost-effectiveness in 45% and 64% of scenarios, respectively.
View Article and Find Full Text PDF

Objectives: Long-term real-world management of inflammatory rheumatic diseases remains unclear, especially with the advent of new treatment options. This study characterizes the number of advanced treatments used by patients with selected rheumatic diseases (rheumatoid arthritis [RA], psoriatic arthritis [PsA], ankylosing spondylitis, juvenile idiopathic arthritis) and provides a contemporary portrait of treatment patterns and therapeutic sequencing among patients with RA and PsA.

Method: Patients were selected from a large US claims database and classified into disease subsamples based on the latest rheumatic diagnosis recorded before/on the day of initiation of the first advanced treatment (index date).

View Article and Find Full Text PDF

Introduction/objectives: The objective of this study is to describe the treatment patterns and use of healthcare resources in a cohort of Colombian patients with rheumatoid arthritis (RA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) or tofacitinib.

Method: This is a descriptive study from a retrospective cohort of patients diagnosed with RA who were treated with bDMARDs or tofacitinib after failure of conventional DMARDs (cDMARDs) or first bDMARD. Patients who were receiving pharmacological treatment between 01 January 2014 and 30 June 2018 were included.

View Article and Find Full Text PDF

Introduction: Widespread use of ten-valent (Synflorix™, GSK) or 13-valent (Prevenar 13™; Pfizer) conjugate vaccination programs has effectively reduced invasive pneumococcal disease (IPD) globally. However, IPD caused by serotypes not contained within the respective vaccines continues to increase, notably serotypes 3, 6A, and 19A in countries using lower-valent vaccines. Our objective was to estimate the clinical and economic benefit of replacing PCV10 with PCV13 in Colombia, Finland, and The Netherlands.

View Article and Find Full Text PDF

Oocyte developmental competence is the ability of the mature oocyte to be fertilized and subsequently drive early embryo development. Developmental competence is acquired by completion of oocyte maturation, a process that includes nuclear (meiotic) and cytoplasmic (molecular) changes. Given that maturing oocytes are transcriptionally quiescent (as are early embryos), they depend on post-transcriptional regulation of stored transcripts for protein synthesis, which is largely mediated by translational repression and deadenylation of transcripts within the cytoplasm, followed by recruitment of specific transcripts in a spatiotemporal manner for translation during oocyte maturation and early development.

View Article and Find Full Text PDF

Background: Food allergy is an abnormal immunological response following exposure (usually ingestion) to a food. Elimination of the allergen is the principle treatment for food allergy, including allergy to fruit. Accidental ingestion of allergenic foods can result in severe anaphylactic reactions.

View Article and Find Full Text PDF

Molecular changes occurring during mammalian oocyte maturation are partly regulated by cytoplasmic polyadenylation (CP) and affect oocyte quality, yet the extent of CP activity during oocyte maturation remains unknown. Single bovine oocyte RNA sequencing (RNA-Seq) was performed to examine changes in transcript abundance during in vitro oocyte maturation in cattle. Polyadenylated RNA from individual germinal-vesicle and metaphase-II oocytes was amplified and processed for Illumina sequencing, producing approximately 30 million reads per replicate for each sample type.

View Article and Find Full Text PDF